Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Announces Appointment of Dr. Aaron Schwartz to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 7, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals First Quarter 2015 Conference Call & Webcast Scheduled for Wednesday, May 13
REHOVOT, Israel and BRIDGEWATER, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Closing of Its $69 Million Public Offering of Ordinary Shares
REHOVOT, Israel, and BRIDGEWATER, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Upsizing and Pricing of its $60 Million Public Offering of Ordinary Shares
 REHOVOT, Israel, and BRIDGEWATER, N.J. -- April 15, 2015 -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the pricing
Toggle Summary Foamix Pharmaceuticals Ltd. Files Registration Statement for Proposed Follow-On Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., April 1, 2015 -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced it has filed a
Toggle Summary Foamix Reports Financial Results for the Year Ended December 31, 2014
Rehovot, Israel – March 18, 2015 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced financial results for the
Toggle Summary Foamix Pharmaceuticals Fourth Quarter 2014 Conference Call & Webcast Scheduled for Wednesday, March 18, 2015
Rehovot, Israel, and Bridgewater, NJ – March 10, 2015 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix to Present Corporate Overview at the 27th Annual ROTH Conference
Rehovot, Israel and Bridgewater, NJ – March 4, 2015 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today
Toggle Summary Foamix to Present Corporate Overview at the Barclays Global Healthcare Conference
Rehovot, Israel and Bridgewater, NJ – March 3, 2015 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today
Toggle Summary Foamix to Present Corporate Overview at the Cowen & Company 35th Annual Health Care Conference
Rehovot, Israel and Bridgewater, NJ – February 26, 2015 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Notice of extraordinary general meeting of shareholders Dec 29, 2014
2 Holzman Street, Weizmann Science Park Rehovot, Israel November 24, 2014 ________________________________ NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 29, 2014 ________________________________ Dear Shareholders: We cordially invite you to attend an Extraordinary
Toggle Summary Foamix Earns US$ 2.5 million Milestone Payment from Bayer HealthCare
Rehovot, Israel and Bridgewater, NJ – December 16, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage specialty pharmaceutical company, announces the receipt of a milestone payment of US$ 2.5 million from Bayer HealthCare. According to a license agreement between the two companies
Toggle Summary Foamix to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference
Rehovot, Israel and Bridgewater, NJ – December 5, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
Rehovot, Israel – November 14, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announces financial results for
Toggle Summary Foamix Announces Two New U.S. Patents Relating to Topical Tetracycline Compositions
New Patents Provide Additional Coverage for Lead Product Candidates FMX101, FMX102, and FDX104   Rehovot, Israel and Bridgewater, NJ – November 13, 2014 – Foamix Pharmaceuticals Ltd. (“Foamix Pharmaceuticals”), a clinical-stage, specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Pharmaceuticals Third Quarter 2014 Conference Call & Webcast Scheduled for Monday, November 17, 2014
Rehovot, Israel, and Bridgewater, NJ – November 10, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 4th in New York City
Rehovot, Israel, and Bridgewater, NJ - October 29, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Initiation of Phase II Trial with FDX104 in Chemotherapy Induced Rash
Rehovot, Israel, and Bridgewater, NJ –    October 6, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”, or “Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Closing of Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 23, 2014 (GLOBE NEWSWIRE) --    Foamix Pharmaceuticals Ltd. ( FOMX ), ("Foamix Pharmaceuticals" or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address
Toggle Summary Foamix Pharmaceuticals Ltd. Prices Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) --   Foamix Pharmaceuticals Ltd. ("Foamix Pharmaceuticals", or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in